Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization

BACKGROUND

Programmed death 1 (PD-1) is an immunologic checkpoint that limits immune responses by delivering potent inhibitory signals to T cells on interaction with specific ligands expressed on tumor/virus-infected cells, thus contributing to immune escape mechanisms. Therapeutic PD-1 blockade has been shown to mediate tumor eradication with impressive clinical results. Little is known about the expression/function of PD-1 on human natural killer (NK) cells.

OBJECTIVE

We sought to clarify whether human NK cells can express PD-1 and analyze their phenotypic/functional features.

METHODS

We performed multiparametric cytofluorimetric analysis of PD-1⁺ NK cells and their functional characterization using degranulation, cytokine production, and proliferation assays.

RESULTS

We provide unequivocal evidence that PD-1 is highly expressed (PD-1^bright) on an NK cell subset detectable in the peripheral blood of approximately one fourth of healthy subjects. These donors are always serologically positive for human cytomegalovirus. PD-1 is expressed by CD56^dim but not CD56^bright NK cells and is confined to fully mature NK cells characterized by the NKG2A^-KIR⁺CD57⁺ phenotype. Proportions of PD-1^bright NK cells were higher in the ascites of a cohort of patients with ovarian carcinoma, suggesting their possible induction/expansion in tumor environments. Functional analysis revealed a reduced proliferative capability in response to cytokines, low degranulation, and impaired cytokine production on interaction with tumor targets.

CONCLUSIONS

We have identified and characterized a novel subpopulation of human NK cells expressing high levels of PD-1. These cells have the phenotypic characteristics of fully mature NK cells and are increased in patients with ovarian carcinoma. They display low proliferative responses and impaired antitumor activity that can be partially restored by antibody-mediated disruption of PD-1/programmed death ligand interaction.